|
ИСТИНА |
Войти в систему Регистрация |
Интеллектуальная Система Тематического Исследования НАукометрических данных |
||
Insulin-like growth factors in the blood of patients with oral squamous cell carcinoma receiving therapy with monoclonal antibodies (cetuximab)статья
Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или ScopusДата последнего поиска статьи во внешних источниках: 20 июня 2024 г.
- Авторы: Lyanova Aza A., Frantsiyants Elena M., Vladimirova Liubov Yu, Neskubina Irina V., Surikova Ekaterina I., Engibaryan Marina A., Abramova Natalia A., Popova Irina L., Tikhanovskaya Natalia M., Teplyakova Maria A., Novoselova Kristina A., Ryadinskaya Ludmila A., Myagkova Valeriya S., Fomenko Yuriy A., Kit Oleg I.
- Журнал: Journal of Clinical Oncology
- Том: 38
- Номер: 15_suppl
- Год издания: 2020
- Издательство: American Society of Clinical Oncology
- Местоположение издательства: United States
- Первая страница: e18564
- Последняя страница: e18564
- DOI: 10.1200/jco.2020.38.15_suppl.e18564
- Аннотация: Background: IGF-1 and IGF-2 are powerful mitogenic factors with anti-apoptotic effect. Their overproduction leads to neoangiogenesis and metastasis. Monitoring the level of these factors can serve as a potential predictive tool. The purpose of the study was to study blood levels of IGF-1 and IGF-2 in patients with squamous cell carcinoma (SCC) of the oral cavity depending of the efficacy of chemotherapy (CT) and cetuximab. Methods: The study included 50 patients with squamous cell carcinoma of the oral cavity T3-4N0-1M0, stage III-IV. The main group (n = 30) received 2 CT cycles with cetuximab: cisplatin 100 mg/m2, intravenously, day 1, 5-fluorouracil 1000 mg/m2/day, intravenously, 96-hour continuous infusion, in combination with cetuximab 400 mg/m2 on day 1 in a loading dose, then 250 mg/m2 on days 8 and 15. The control group (n = 20) received 2 CT cycles: intravenous cisplatin 100 mg/m2 on day 1, intravenous 5-fluorouracil 1000 mg/m2/day, 96-hour continuous infusion on days 1-4. Results were compared with the values in 20 non-cancer donors. Levels of IGF-1 (mcg/L) and IGF-2 (ng/mL) were measured in the blood serum by ELISA using standard test systems (Mediagnost, Germany). Statistical analysis of results was performed using the Statistica 6.0 program (Stat-Soft, 2001). Results: Before treatment, levels of IGF-1 and IGF-2 in patients were lower than in donors by 53.5% and 20.3%, respectively. In patients with partial regression after CT, IGF-1 levels significantly increased by 33% (p < 0,05), compared to the values before treatment, while IGF-2 was both within donor and initial values and the IGF-1/IGF-2 ratio was similar to the initial level but 33.3% lower than in donors. The patients in the main group with partial regression normalized IGF-1 levels increasing it compared to initial values – by 87%. IGF-2 levels did not differ statistically significantly from the initial values and were 32.5% lower than in donors. The IGF-1/IGF-2 ratio was 58% higher than before treatment. Conclusions: CT and cetuximab normalized blood levels of IGF-1 in oral cancer patients with partial tumor regression.
- Добавил в систему: Владимирова Любовь Юрьевна